Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Acosta

Showing results (1-10 of 338) with videos related to

Pageof 34
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Pharmacokinetic enhancement of protease inhibitorsE P Acosta
Angiologia|September 1, 1993
[Prosthesis interposition in the case of subclavian artery transposition]G György, P Acosta Alvarez
Clinical Pharmacology and Therapeutics|October 1, 2010
Determination of appropriate dosing of influenza drugs in pediatric patientsE P Acosta, D W Kimberlin
The Annals of Pharmacotherapy|February 1, 1997
ValacyclovirE P Acosta, C V Fletcher
Journal of Acquired Immune Deficiency Syndromes (1999)|July 5, 2003
Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1Edward P Acosta, Henry H Balfour
Clinical Chemistry|December 6, 2000
Long-term stability of nelfinavir mesylate in human plasmaM L Turner, E P Acosta
International Journal of Antimicrobial Agents|April 1, 1995
Antiretroviral drug interactionsE P Acosta, C V Fletcher
Clinical Pharmacokinetics|June 29, 2006
Tipranavir: a novel nonpeptidic protease inhibitor of HIVJennifer R King, Edward P Acosta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2020
Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral RegimensDavid W Haas, Edward P Acosta
AIDS Research and Human Retroviruses|August 31, 2002
Position paper on therapeutic drug monitoring of antiretroviral agentsEdward P Acosta, John G Gerber,
Pageof 34

Showing results (1-10 of 338) with videos related to

Sort By:
Pageof 34
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Pharmacokinetic enhancement of protease inhibitorsE P Acosta
Angiologia|September 1, 1993
[Prosthesis interposition in the case of subclavian artery transposition]G György, P Acosta Alvarez
Clinical Pharmacology and Therapeutics|October 1, 2010
Determination of appropriate dosing of influenza drugs in pediatric patientsE P Acosta, D W Kimberlin
The Annals of Pharmacotherapy|February 1, 1997
ValacyclovirE P Acosta, C V Fletcher
Journal of Acquired Immune Deficiency Syndromes (1999)|July 5, 2003
Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1Edward P Acosta, Henry H Balfour
Clinical Chemistry|December 6, 2000
Long-term stability of nelfinavir mesylate in human plasmaM L Turner, E P Acosta
International Journal of Antimicrobial Agents|April 1, 1995
Antiretroviral drug interactionsE P Acosta, C V Fletcher
Clinical Pharmacokinetics|June 29, 2006
Tipranavir: a novel nonpeptidic protease inhibitor of HIVJennifer R King, Edward P Acosta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2020
Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral RegimensDavid W Haas, Edward P Acosta
AIDS Research and Human Retroviruses|August 31, 2002
Position paper on therapeutic drug monitoring of antiretroviral agentsEdward P Acosta, John G Gerber,
Pageof 34